Impax Asset Management Group plc trimmed its stake in shares of Zoetis Inc. (NYSE:ZTS – Free Report) by 20.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 175,957 shares of the company’s stock after selling 44,441 shares during the quarter. Impax Asset Management Group plc’s holdings in Zoetis were worth $12,287,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors and hedge funds have also made changes to their positions in ZTS. University of Texas Texas AM Investment Management Co. acquired a new position in shares of Zoetis during the second quarter valued at $25,000. Dunhill Financial LLC grew its position in shares of Zoetis by 519.3% during the second quarter. Dunhill Financial LLC now owns 353 shares of the company’s stock worth $25,000 after acquiring an additional 296 shares during the last quarter. Cassaday & Co Wealth Management LLC acquired a new stake in shares of Zoetis in the 1st quarter worth about $28,000. First Command Advisory Services Inc. increased its holdings in shares of Zoetis by 3,881.8% in the 3rd quarter. First Command Advisory Services Inc. now owns 438 shares of the company’s stock worth $31,000 after acquiring an additional 427 shares during the period. Finally, Wellington Grp LLC increased its holdings in shares of Zoetis by 6,675.0% in the 1st quarter. Wellington Grp LLC now owns 271 shares of the company’s stock worth $32,000 after acquiring an additional 267 shares during the period. 92.80% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
Several brokerages recently weighed in on ZTS. Zacks Research upgraded shares of Zoetis from a “strong sell” rating to a “hold” rating in a research report on Monday, October 26th. William Blair cut shares of Zoetis from an “outperform” rating to a “market perform” rating in a research report on Thursday, August 6th. JPMorgan Chase & Co. decreased their target price on shares of Zoetis from $130.00 to $115.00 and set an “overweight” rating for the company in a research report on Friday, August 7th. Morgan Stanley dropped their price target on shares of Zoetis from $85.00 to $82.00 and set an “overweight” rating on the stock in a research note on Thursday, October 29th. Finally, TD Cowen cut their price target on Zoetis from $104.00 to $94.00 and set a “buy” rating on the stock in a report on Tuesday, August 25th. Eight analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $101.25.
Get Our Latest Stock Report on Zoetis
Zoetis Trading Up 2.5%
Shares of ZTS stock opened at $85.56 on Thursday. Zoetis Inc. has a 1 year low of $68.77 and a 1 year high of $132.49. The firm has a market capitalization of $34.76 billion, a PE ratio of 14.55, a price-to-earnings-growth ratio of 1.21 and a beta of 0.67. The stock has a fifty day moving average of $76.88 and a two-hundred day moving average of $90.98. The company has a debt-to-equity ratio of 2.51, a quick ratio of 1.40 and a current ratio of 2.35.
Zoetis (NYSE:ZTS – Get Free Report) last issued its quarterly earnings results on Thursday, November 5th. The company reported $1.75 EPS for the quarter, beating analysts’ consensus estimates of $1.51 by $0.24. The company had revenue of $2.39 billion for the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a return on equity of 85.90% and a net margin of 26.15%. The company’s quarterly revenue was down 1.3% compared to the same quarter last year. During the same period last year, the company earned $1.70 earnings per share. As a group, research analysts expect that Zoetis Inc. will post 6.29 EPS for the current year.
Zoetis Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 1st. Investors of record on Friday, October 30th will be issued a $0.53 dividend. The ex-dividend date of this dividend is Friday, October 30th. This represents a $2.12 annualized dividend and a yield of 2.5%. Zoetis’s dividend payout ratio is presently 36.05%.
About Zoetis
Zoetis is an animal health company that discovers, develops, manufactures and markets medicines, vaccines, diagnostic products and other services for animals. Its products support both companion animals, such as dogs and cats, and livestock, including cattle, pigs, poultry, sheep and fish. The company’s offerings include treatments for pain, infections and skin conditions, as well as vaccines, parasiticides, diagnostic tools and genetic testing services. Zoetis serves veterinarians, livestock producers and other animal health professionals around the world.
See Also
- Five stocks we like better than Zoetis
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Free Report).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.
